We have entered a new era of improved and emerging biologically-based diagnostic biomarkers for Alzheimer’s disease (AD) and AD-related neurodegenerative disorders (ADRD) that are rapidly impacting evaluation and care paradigms in every clinical setting: primary care, specialty care and dementia subspecialty care.
Senti Bio offloads manufacturing site to Hong Kong PE firm for $38M
San Francisco-based preclinical biotech Senti Biosciences is selling off a manufacturing facility to a private equity firm that’s spinning it into a new contract manufacturer